AbbVie will pay Genmab $750 million upfront, and potentially up to $3.15 billion in additional development, regulatory and sales milestone paymentsOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.